- Home
- SXTP vs APVO Comparison
SXTP vs APVO Comparison
Compare SXTP & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- APVO
- Stock Information
- Founded
- SXTP 2010
- APVO 2016
- Country
- SXTP United States
- APVO United States
- Employees
- SXTP N/A
- APVO N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- APVO Health Care
- Exchange
- SXTP Nasdaq
- APVO Nasdaq
- Market Cap
- SXTP 4.3M
- APVO 4.1M
- IPO Year
- SXTP 2023
- APVO N/A
- Fundamental
- Price
- SXTP $2.32
- APVO $3.23
- Analyst Decision
- SXTP Buy
- APVO Strong Buy
- Analyst Count
- SXTP 2
- APVO 1
- Target Price
- SXTP $7.00
- APVO $5,920.00
- AVG Volume (30 Days)
- SXTP 324.9K
- APVO 6.6M
- Earning Date
- SXTP 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- SXTP N/A
- APVO N/A
- EPS Growth
- SXTP N/A
- APVO N/A
- EPS
- SXTP N/A
- APVO N/A
- Revenue
- SXTP $802,323.00
- APVO N/A
- Revenue This Year
- SXTP $95.50
- APVO N/A
- Revenue Next Year
- SXTP $80.78
- APVO N/A
- P/E Ratio
- SXTP N/A
- APVO N/A
- Revenue Growth
- SXTP 118.37
- APVO N/A
- 52 Week Low
- SXTP $1.41
- APVO $2.81
- 52 Week High
- SXTP $35.99
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- SXTP 50.64
- APVO 34.28
- Support Level
- SXTP $1.91
- APVO $2.81
- Resistance Level
- SXTP $2.55
- APVO $13.11
- Average True Range (ATR)
- SXTP 0.24
- APVO 1.10
- MACD
- SXTP -0.00
- APVO 0.30
- Stochastic Oscillator
- SXTP 46.09
- APVO 4.08
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.